Literature DB >> 2013505

A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection.

K Yoshioka1, D J Youngs, M R Keighley.   

Abstract

A prospective randomised study was undertaken in 80 patients to assess the combined regimen of ciprofloxacin with metronidazole against amoxicillin/clavulanic acid with metronidazole as treatment for established intra-abdominal infection. Treatment was for five days. Seventy-eight patients were clinically evaluable (38 patients on ciprofloxacin with metronidazole and 40 patients on amoxicillin/clavulanic acid with metronidazole). The overall clinical success rate in the treatment of intra-abdominal infections was 96% for the ciprofloxacin with metronidazole group, and 90% for the amoxicillin/clavulanic acid with metronidazole group. Over half of all patients were able to change from intravenous to oral antibiotic administration within the study period. One patient receiving ciprofloxacin with metronidazole developed pruritus near the injection site.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013505     DOI: 10.1007/bf01643754

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  18 in total

1.  In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

2.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

Review 3.  Tissue penetration of the new quinolones in humans.

Authors:  D N Gerding; J A Hitt
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

4.  Intraperitoneal penetration of ciprofloxacin.

Authors:  M R Lockley; R Waldron; R Wise; I A Donovan
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

5.  The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

Authors:  A King; K Shannon; I Phillips
Journal:  J Antimicrob Chemother       Date:  1984-04       Impact factor: 5.790

6.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.

Authors:  P A Hunter; K Coleman; J Fisher; D Taylor
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

7.  The penetration of amoxycillin/clavulanic acid into peritoneal fluid.

Authors:  R Wise; I A Donovan; J Drumm; J M Andrews; P Stephenson
Journal:  J Antimicrob Chemother       Date:  1983-01       Impact factor: 5.790

8.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

9.  Metronidazole and Augmentin in the prevention of sepsis after appendicectomy.

Authors:  J Drumm; I A Donovan; R Wise; P Lowe
Journal:  Br J Surg       Date:  1985-07       Impact factor: 6.939

10.  Sepsis score and acute-phase protein response as predictors of outcome in septic surgical patients.

Authors:  L Dominioni; R Dionigi; M Zanello; R Monico; R Cremaschi; R Dionigi; A Ballabio; M Massa; M Comelli; P Dal Ri
Journal:  Arch Surg       Date:  1987-02
View more
  5 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Sequential antimicrobial therapy: a realistic approach to cost containment?

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 3.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 4.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 5.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.